- To serve as an important medium for the publication of original research in the field of medical science and health research, thus filling gaps in health knowledge for effective utilization of research findings
- To impart current medical knowledge and updated scientific information obtained from research to health professionals for better and appropriate health care management
- To disseminate recent basic, applied and social research findings among health personnel of different strata for enhancing worldwide health development
Archives 2021
Myanmar Health Sciences Research Journal
Volume 33, Number 1
TITLE: Human Papilloma Virus (HPV) DNA Testing Followed by HPV Genotyping Based Cervical Cancer Screening in Magway Region
AUTHOR: Mu Mu Shwe, Khin May Thin, Lei Lei Aye Thaung, Lynn Pa Pa Aye, Kham Mo Aung, May Zon Myint, Htwe Htwe Nyunt, Kyaw Soe Tun & Win Maw Tun
SOURCE: Myanmar Health Sciences Research Journal, 2021: 33,(1-3): 74- 82
ABSTRACT:
Human Papillomavirus (HPV) is the primary cause of cervical cancer, the first leading cause of female cancer in Myanmar. So, screening women for the presence of HPV is a critical aspect for prevention and early treatment of cervical cancer. The objectives were to conduct HPV DNA testing followed by HPV genotyping based Cervical Cancer Screening in Magway Region and to identify the cervical histological abnormalities among women who have HPV infection. It was a prospective cross-sectional descriptive study. Total of asymptotic 6 married women (median age 0 years; range 0-50) residing in Magway Region were screened in 09. Cervical cells were obtained by sterile disposable careBrush and collected in careHPV Collection Medium. HPV-DNA-testing was performed using careHPV test which detects pooled--high-risk-HPV-6, -8, -, -, -5, -9, -5, -5, -5, -56, -58, -59, -66 and -68. HPV-positive-cases were followed by colposcopy-directed-biopsy and histology and HPV6/8 genotyping using GeneXpert HPV -Test. HPV was identified in 6.% of screened women in Magway Region. Among HPV-positive cases, other-HR-HPV-genotypes (HPV -, -, -5, -9, -5, -5, -56, -58, -59, -66 and -68) were 75%, HPV -6 (.5%) and HPV-8/5 (.5%).
SUBJECT HEADINGS: Cervical Cancer Screening, HPV DNA testing, HPV genotyping, Histopathology
FULL TEXT:
